Abstract 1059P
Background
The impact of the duration of tumor persistence within the host – tumor longevity (TL) – on patient (pt) outcomes under immune checkpoint inhibitors (ICIs) is unexplored. We hypothesized that this time parameter may influence ICIs efficacy. We investigated this association in head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), and renal/urothelial cancer (R/UC) pts.
Methods
Retrospective, observational study including adult pts with primary/recurrent HNSCC, NSCLC, R/UC receiving ICIs (≥first line) in 2 Italian centers. Endpoints were the association between TL and: 1) progressive disease (PD) vs. complete response (CR)/ partial response (PR)/ stable disease (SD); 2) Common Terminology Criteria for Adverse Events (CTCAE) G≥3 toxicity; 3) overall survival (OS). Univariable/multivariable logistic regression model (for PD, toxicity) and Cox proportional hazards model (for OS) were used. TL, defined as time from cancer histological diagnosis to ICIs start, was included as continuous variable using 3 knots restricted cubic spline, comparing third (Q3) vs. first (Q1) quartiles.
Results
304 pts, diagnosed in 2002-2022, started ICIs in 2014-2022. TL had a right-skewed distribution [median: 15.3 (Q1-Q3, 5.5; 33.1) months]. CR, PR, SD, PD occurred in 16 (5.3%), 90 (29.6%), 65 (21.4%), 133 (43.7%) pts, respectively; G≥3 toxicity was reported in 16 (5.3%) pts and 231 (76.0%) pts died. Multivariable models adjusted for relevant variables (Table) suggested that longer TL was associated with lower PD odds (Odds Ratio [OR] Q3 vs. Q1 = 0.31; 95% CI 0.12; 0.81, p = 0.004), higher G≥3 toxicity odds (OR = 1.27; 95% CI 0.39; 4.12), lower death risk (Hazard Ratio = 0.79; 95% CI 0.49; 1.28). Table: 1059P
| Descriptive statistics (N=304) | ||
| Sex | Male | 243 (79.9%) |
| Age at diagnosis (years) | Mean (SD) | 64.7 (10.4) |
| Smoking history | Yes | 226 (74.3%) |
| No | 57 (18.8%) | |
| Unknown | 21 (6.9%) | |
| Primary site | NSCLC | 138 (45.4%) |
| HNSCC | 112 (36.5%) | |
| R/UC | 54 (17.8%) | |
| Stage at diagnosis | IV | 199 (65.5%) |
ConclusionsOur real-world, hypothesis-raising results indicate that longer TL may lead to improved response to ICIs, higher risk of G≥3 toxicity and longer OS. Clinical trial identificationEditorial acknowledgementLegal entity responsible for the studyThe authors. FundingAuthors at Niguarda Cancer Center are supported by Fondazione Oncologia Niguarda ETS. DisclosureA. Sartore Bianchi: Financial Interests, Personal, Advisory Board: Amgen, Servier, Novartis; Financial Interests, Personal, Invited Speaker: Bayer, Guardant Health, Pierre Fabre. S. Siena: Financial Interests, Advisory Board: Agenus, Amgen, AstraZeneca, Bayer, BMS, CheckmAb, Clovis, Daiichi Sankyo, Merck, Novartis, Roche-Genentech, Seattle Genetics. L.F.L. Licitra: Financial Interests, Personal, Advisory Board, for expert opinion in advisory boards: AstraZeneca, Bayer, BMS, Eisai, MSD, Boehringer Ingelheim, F. Hoffmann-La Roche Ltd, Novartis, Roche, Debiopharm International SA, Sobi, Incyte Biosciences Italy srl, Doxa Pharma srl, Amgen, Nanobiotics, GSK; Financial Interests, Institutional, Research Grant, Funds received by my institution for clinical studies and research activities in which I am involved: AstraZeneca, BMS, Boehringer Ingelheim, Celgene International, Eisai, Exelixis, Debiopharm International SA, F. Hoffmann-La Roche ltd, IRX Therapeutics, Medpace, Merck-Serono, Merck Healthcare KGaA, MSD, Novartis, Pfizer, Roche, Adlai Nortye. All other authors have declared no conflicts of interest. Resources from the same session1014P - Phase Ib trial results of safety, pharmacokinetics and pharmacodynamics of TU2218, TGFβ-RI and VEGF-R2 dual inhibitor in combination with pembrolizumab in patients with advanced solid tumorsPresenter: Anthony Tolcher Session: Poster session 03 1015P - The efficacy and mechanism of pan-FGFR inhibitor (AZD4547) combined with immunoagonists or immunosuppressants in FGFR-positive tumorsPresenter: Qizhi Ma Session: Poster session 03 1016P - Phase I study of SOF10 plus atezolizumab in patients with advanced/recurrent solid tumoursPresenter: Toshihiko Doi Session: Poster session 03 1017P - Updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC)Presenter: Samuel Klempner Session: Poster session 03 1018P - Leveraging innate and adaptive immunity with AFM24 and atezolizumab in metastatic gastric cancerPresenter: Omar Saavedra Santa Gadea Session: Poster session 03 1019P - Bispecific PD1-IL2 antibody reshapes the inhibitory immune microenvironment of SMARCA4 mutant non-small cell lung cancer by reversing CD8+T cell exhaustionPresenter: Bo Cheng Session: Poster session 03 Resources: Abstract 1020P - Highly potent and specific bivalent T cell engager (TCE) targeting PRAME on HLA-A*02:01Presenter: Athanasia Dasargyri Session: Poster session 03 1021P - Chemotherapy and hypomethylating agents enhance anti-tumor activity of PRAME ImmTACPresenter: Adel Benlahrech Session: Poster session 03 1022P - A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: Completed cohort for first-line (1L) treatment of advanced squamous cell carcinoma of the head and neck (SCCHN)Presenter: Jonathan Riess Session: Poster session 03 1023P - Long-term follow up of patients treated with a DNA vaccine (pTVG-HP) for PSA-recurrent prostate cancerPresenter: Douglas McNeel Session: Poster session 03 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|